JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.

Abstract

BACKGROUND:

As a commonly mutated form of the epidermal growth factor receptor, EGFRvIII strongly promotes glioblastoma (GBM) tumor invasion and progression, but the mechanisms underlying this promotion are not fully understood.

METHODS:

Through gene manipulation, we established EGFRvIII-, wild-type EGFR-, and vector-expressing GBM cells. We used cDNA microarrays, bioinformatics analysis, target-blocking migration and invasion assays, Western blotting, and an orthotopic U87MG GBM model to examine the phenotypic shifts and treatment effects of EGFRvIII expression in vitro and in vivo. Confocal imaging, co-immunoprecipitation, and siRNA assays detected the focal adhesion-associated complex and their relationships to the EGFRvIII/JAK2/STAT3 axis in GBM cells.

RESULTS:

The activation of JAK2/STAT3 signaling is vital for promoting migration and invasion in EGFRvIII-GBM cells. AG490 or WP1066, the JAK2/STAT3 inhibitors, specifically destroyed EGFRvIII/JAK2/STAT3-related focal adhesions and depleted the activation of EGFR/Akt/FAK and JAK2/STAT3 signaling, thereby abolishing the ability of EGFRvIII-expressing GBM cells to migrate and invade. Furthermore, the RNAi silencing of JAK2 in EGFRvIII-expressing GBM cells significantly attenuated their ability to migrate and invade; however, as a result of a potential EGFRvIII-JAK2-STAT3 activation loop, neither EGFR nor STAT3 knockdown yielded the same effects. Moreover, AG490 or JAK2 gene knockdown greatly suppressed tumor invasion and progression in the U87MG-EGFRvIII orthotopic models.

CONCLUSION:

Taken together, our data demonstrate that JAK2/STAT3 signaling is essential for EGFRvIII-driven migration and invasion by promoting focal adhesion and stabilizing the EGFRvIII/JAK2/STAT3 axis. Targeting JAK2/STAT3 therapy, such as AG490, may have potential clinical implications for the tailored treatment of GBM patients bearing EGFRvIII-positive tumors.

• Authors: Qifan Zheng, Lei Han, Yucui Dong, Jing Tian, Wei Huang, Zhaoyu Liu, Xiuzhi Jia, Tao Jiang, Jianning Zhang, Xia Li, Chunsheng Kang, Huan Ren
• Journal: Neuro-oncology (Neuro Oncol) Vol. 16 Issue 9 Pg. 1229-43 (Sep 2014) ISSN: 1523-5866 [Electronic] England
• PMID: 24861878 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antineoplastic Agents
• Enzyme Inhibitors
• STAT3 Transcription Factor
• STAT3 protein, human
• Tyrphostins
• alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
• epidermal growth factor receptor VIII
• ErbB Receptors
• Janus Kinase 2

Topics

• Animals
• Antineoplastic Agents (administration & dosage)
• Brain Neoplasms (drug therapy, metabolism, pathology)
• Cell Line, Tumor
• Enzyme Inhibitors (administration & dosage)
• ErbB Receptors (metabolism)
• Focal Adhesions (drug effects, metabolism)
• Glioblastoma (drug therapy, metabolism, pathology)
• Humans
• Janus Kinase 2 (metabolism)
• Mice
• Mice, Nude
• Neoplasm Invasiveness
• STAT3 Transcription Factor (metabolism)
• Signal Transduction (drug effects)
• Tyrphostins (administration & dosage)